The economic impact of smoking on the treatment costs of stroke at a tertiary care neurological center in Mexico

Authors

  • Roger Humberto Quintana-Carrillo,

    1. Departamento de Investigación sobre Tabaco, Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México
    Search for more papers by this author
  • Antonio Arauz,

    1. Clínica de ECV, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, México
    Search for more papers by this author
  • Daniel San-Juan,

    1. Dirección de Investigación, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, México
    Search for more papers by this author
  • Iván Tomás López de Santiago,

    1. Clínica de ECV, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, México
    Search for more papers by this author
  • Lucinda Aguirre-Cruz,

    1. Dirección de Investigación, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, México
    Search for more papers by this author
  • Teresa Corona,

    1. Dirección General, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, México
    Search for more papers by this author
  • Luz Myriam Reynales-Shigematsu

    Corresponding author
    • Departamento de Investigación sobre Tabaco, Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México
    Search for more papers by this author

Correspondence: Luz Myriam Reynales-Shigematsu*, Departamento de Investigación sobre Tabaco, Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Av. Universidad 655, 1er. Piso Col. Santa María Ahuacatitlan, 62100 Cuernavaca, Morelos. México.

E-mail: lreynales@correo.insp.mx

Dear Editor,

Although tobacco smoking is an independent risk factor for cerebrovascular disease (CVD) [1, 2], CVD health-care costs generated by smoking remain unknown in many countries [3, 4], including Mexico [5]. To estimate the direct health-care cost of CVD from a provider's perspective, we conducted a cost of illness (COI) analysis using data from the medical records of patients who visited the Mexican National Institute of Neurology and Neurosurgery in 2010. Cost estimates in Mexican pesos were converted into US dollars using the 2010 FIX exchange rate for foreign transactions. The fraction of CVD costs attributable to smoking was used to estimate the costs of smoking.

The total cost of smoking-attributable CVD at our center in 2010 was $1 179 607. The average annual cost per patient by CVD type was $3904 for ischemic stroke, $6098 for hemorrhagic stroke, $2416 for cerebral venous thrombosis, and $11 477 for subarachnoid hemorrhage. The medical care costs of newly diagnosed with CVD patients are mainly attributable to immediate care in the emergency room and initial hospitalization, when the patient is stabilized and diagnostic tests are conducted (Fig. 1). This study in a developing country confirmed the high direct medical care costs of patients with CVD attributable to smoking. Implementing the WHO Framework Convention of Tobacco Control should work to reduce these costs.

Figure 1.

Percentage frequency distribution of total costs by type of event and type of cerebrovascular disease.

Ancillary